Abramson, J. L., & Vaccarino, V. (2002). Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 162(11): 1286-1292.

Ballantyne, C., et al. (2003). Lipoprotein-Associated Phospholipase A2 and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the ARIC Study. Unpublished data. Presented at the American College of Cardiology on May 2, 2003.

Castelli, W, et al. (1996). Lipids, risk factors and ischemic heart disease. Atherosclerosis 124(Suppl):S1-9.

Church, T. S., Bartlow, C. E., Earnest, C.P., et al., (2002). Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 22(11): 1869-1876.

Dada N, et al. (2002). Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev. Mol. Diagn. 2(1), 17-22.

Esposito, K., Pontillo, A., DiPalo, C, et al. (2003). Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA, 289(14): 1799-1804.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001, 285: 2486-2497.

Festa, A., D’Agostine, R., Jr., Tracy, R. P., & Huffier, S. M. (2002). C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects: The Insulin Resistance Atherosclerosis Study. Diabetic Med, 19(11): 939-943.

Ford, E. S. (2002). Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology, 13(5): 561-568.

Freinkel, S. (2003, July/August). CRP screening may be the best weapon against heart disease since cholesterol testing. Health: 45-50.

Gabay, C., & Kushner, I. (1999). Acute-phase and other systemic responses to inflammation. N Engl J Med, 340: 448-454.

Huerta, M. G., & Nadler, J. L. (2002). Role inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Curr Diab Rep, 2(5): 396-402.

Isasi, C. R., Deckelbaum, R. J., Tracy, R. P., et al. (2003). Physical fitness and C-reactive protein level in children and young adults: The Columbia University BioMarkers Study. Pediatrics, 111(2): 332-338.

Keller, K. B., & Lemberg, L. (2003). Obesity and the metabolic syndrome. Am J Crit Care, 12(2): 167-170.

King, D. E., Carek, P., Mainous, A. G., 3rd., Pearson, W. S. (2003). Inflammatory markers and exercise: Differences related to exercise type. Med Sci Sports Exerc, 35(4): 575-581.

Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. Circulation, 105: 1135-1143.

MacPhee, C, et al. (2001). Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology, 1: 121-125.

Mann, P. J., Williams, D. P., Snow, C.M., & Wonder, R. C. (2003). Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol, 15(1): 91-100.

Mayo Clinic Newsletter. (2003). Novel risk factors: Identifying new culprits in heart disease. Retrieved June 27, 2003: http://www.mayoclinic.com/invoke.cfm?id=HB00031.

MEDLINEPlus Medical Encyclopedia. C-reactive protein. Retrieved June 27, 2003: http://www.nlm.nih.gov/medlineplus/ency/article/00356.htm.

Mold, C., Gewurz, H., & DuClos, T.W. (1999). Regulation of complement activation of C-reactive Protein. Immunopharmocology, 42: 23-30.

Packard CJ, et al. (2000). Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med., 343(16):1179-82.

Pearson, T. A., (2002). New tools for coronary risk assessment: What are their advantages and limitations? Circulation, 105: 886-892.

Pearson, T.A., Mensah, G. A., et al. (2003). Markers of inflammation and cardiovascular disease (Application to clinical and public health practice; A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association). Circulation, 107: 499-511.

Pepys, M. B., & Hirshcfield, G. M. (2003). C-reactive protein: A critical update. J. Clin Invest. 111(12): 1805-1812.

Reynolds, G. D., & Vance R. P. (1987). C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med, 111: 265-269.

Ridker, P. M. (2003). Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107: 363-369.

Ridker, P, M. (2001). Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trail. Eur Heart J., 22: 2135-2137.

Ridker, P. M., Buring, J. E., Cook, N.R., & Rifai, N. (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation, 107: 391-397.

Ridker, P. M., Hennekens, C. H., Buring, J. E., et al., (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342: 836-843.

Ridker, P. M., Rifai, N. Rose, L., et al. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the predication of first cardiovascular events. N Engl J Med., 347: 1557-1565.

Ridker, P. M, Rifai, N., Pfeffer, M., et al. (1999). Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation, 100: 230-235.

Rothenbacher, D., Hoffmeister, A., Brenner, H. Koenigh, W. (2003). Physical activity, coronary heart disease, and inflammatory response. Arch Intern Med, 163(10): 1200-1205.

Saito, I., Yonemasu, K, & Inami, F. (2003). Association of body mass index, body fat, and weight gain with inflammation markers among rural residents in Japan. Circulation, 67: 323-329.

Schwartz, R. S., Bayes-Genis, A., Lesser, J. R., et al. (2003). Detecting vulnerable plaque using peripheral blood: Inflammatory and cellular markers. J Interv Cardiol, 16(3): 231-242.

Suckling, K, et al. (2002). Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opn. Ther. Targets, 6 (3): 1-6.

Tillett, W. S., & Francis T., Jr. (1930). Serological reactions in pneumonia with non-protein somatic fraction of pneumonococcus. J Exp Med, 52: 561-571.

Tsimihodimos T, et al. (2003). Fenofibrate induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity associated with apo B-containing lipoproteins. Journal of Lipid Research, 44(5): 927-34.

Verma, S., Wang, C-H., Weisel, R. D. et al. (2003). Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. Journal of Molecular and Cellular Cardiology, 35: 417-419.

U.S. Public Health Service. (1964). Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. PHS Publication No. 1103.

Yeh, E. T. H., Anderson, H. V., Pasceri V., et al. (2001). C-reactive protein: Linking inflammation to cardiovascular complications. Circulation, 104: 974-975.

Yeh, E. T. H., & Willerson, J. T. (2003). Coming of age of C-reactive protein: Using inflammation markers in cardiology. Circulation, 107: 370-372.